Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about SCFAs: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Target | Relation | Type | Str |
|---|---|---|---|
| FFAR2 | activates | protein | 0.90 |
| FFAR3 | activates | protein | 0.90 |
| FFAR2 | activates | protein | 0.90 |
| FFAR3 | activates | protein | 0.90 |
| alpha-synuclein aggregation | inhibits | process | 0.80 |
| neuroinflammation | inhibits | process | 0.80 |
| Neuroinflammation | modulates | process | 0.70 |
| neuroinflammation | modulates | mechanism | 0.70 |
| NLRP3 inflammasome | modulates | protein | 0.70 |
| GLP1R agonism | associated_with | therapy | 0.70 |
| FFAR2/GPR43 | activates | protein | 0.70 |
| FFAR3/GPR41 | activates | protein | 0.70 |
| alpha-synuclein burden | reduces | phenotype | 0.70 |
| alpha-synuclein burden | regulates | phenotype | 0.70 |
| gut-to-brain propagation | regulates | phenotype | 0.70 |
| NLRP3 Inflammasome | regulates | gene | 0.70 |
| neuronal stress resistance | enhances | phenotype | 0.70 |
| PROTEOSTASIS | regulates | phenotype | 0.70 |
| parkinson-disease | decreases_risk | disease | 0.70 |
| synucleinopathy | regulates | disease | 0.70 |
| proteostasis | modulates | process | 0.50 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Physiological SCFAs may confer indirect anti-synuclein benef | 0.670 | neurodegeneration | Do physiological concentrations of SCFAs |
| Physiological SCFAs may reduce alpha-synuclein burden primar | 0.650 | neurodegeneration | Do physiological concentrations of SCFAs |
| The most realistic translational use of physiological SCFAs | 0.610 | neurodegeneration | Do physiological concentrations of SCFAs |
| Physiological SCFAs may worsen alpha-synuclein pathology thr | 0.550 | neurodegeneration | Do physiological concentrations of SCFAs |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.728
neurodegeneration | 2026-04-26 | 3 hypotheses Top: 0.346
neurodegeneration | 2026-04-24 | 6 hypotheses Top: 0.670
neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.703
neurodegeneration | 2026-04-12 | 2 hypotheses Top: 0.682
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.13 · 2026-04-27
closed · Rounds: 4 · Score: 0.76 · 2026-04-26
closed · Rounds: 3 · Score: 0.75 · 2026-04-26
closed · Rounds: 3 · Score: 0.75 · 2026-04-26
closed · Rounds: 4 · Score: 0.78 · 2026-04-26
closed · Rounds: 4 · Score: 0.63 · 2026-04-24
closed · Rounds: 4 · Score: 0.50 · 2026-04-20
closed · Rounds: 4 · Score: 0.84 · 2026-04-16
closed · Rounds: 4 · Score: 0.70 · 2026-04-12
closed · Rounds: 4 · Score: 0.95 · 2026-04-01
Hypotheses and analyses mentioning SCFAs in their description or question text
No additional research found